BioInvent International AB · OMXSTO:BINV
BioInvent International AB — Investor Day (December 2018)
34 slides from BioInvent International AB's investor day presentation, Dec 10, 2018
Slide 1: Company Presentation
COMPANY PRESENTATION December 2018 1
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or any
Slide 3: Introduction to BioInvent
1. Introduction to BioInvent 2. Development programs 1 – solid cancer focus 3. Management and board1 4. Key milestones 1 A. Appendix 1 3
Slide 4: BioInvent in brief and today's presenters
TODAY’S PRESENTERS Martin Welschof, Ph.D. in brief Chief Executive Office Ph.D. in recombinant antibody technology. Martin has a BioInvent International AB (OMXS: BINV), is focused on the broad international experience from executive positions within the biotech industry, including Director of disco
Slide 5: Investment Highlights
INVESTMENT HIGHLIGTS LEADING ANTIBODY IMMUNO-ONCOLOGY PLATFORM Advancing Cancer Immunotherapy by overcoming tumor resistance Validated by publications in top-tier journals e.g. Cancer Cell, and Immunity and partnerships with leading pharma companies such as Pfizer, Transgene, Bayer Pharma, Dai
Slide 6: BioInvent's History
BIOINVENT’S HISTORY IND approval for BI- Three new clinical programs 1206 by FDA Expanded pipeline with three clinical IND approval for BI-1206 in programs in solid cancer starting H1 combination with rituximab 2019 Collaboration with Pfizer First patient dosed in phase Publication of data in leadin
Slide 7: New drugs and mechanisms are needed to improve cancer immunotherapy
s NEW DRUGS AND MECHANISMS ARE NEEDED TO IMPROVE CANCER IMMUNOTHERAPY & SURVIVAL THE CONCEPT ONLY A SUBSET OF A RAPIDLY WORKS PATIENTS GROWING MARKET RESPOND TO 2016 sales 1 CURRENT DRUGS 43bn (USD) New drugs direct the New mechanisms and immune system to antibodies needed to 2022E sales1 combat tum
Slide 8: BioInvent targets key immune suppressive cells and mechanisms
s BIOINVENT TARGETS KEY IMMUNE SUPPRESSIVE CELLS & MECHANISMS TO BOOST ANTI-CANCER IMMUNITY The cancer immunity cycle 4 Trafficking of T cells to tumors Priming and activation (CTLs) 3 -+ of T cells Tregs1 (CD25+ foxp3+) TAM2/MDSC3 CTL4 Macrophages5 Infiltration of T cells into 5 tumors Cancer antig
Slide 9: F.I.R.S.T. platform for discovery of novel oncology targets and mAb
s F.I.R.S.T™- A PATIENT CENTRIC PLATFORM FOR DISCOVERY OF NOVEL ONCOLOGY TARGETS AND MAB Bioinvent’s proprietary platform Clinically relevant targets & monoclonal antibody (mAb) Platform validated by Pfizer - Pfizer is now using the platform for their tumor associated myeloid cells (TAM) 9
Slide 10: Pipeline – Multiple Value Drivers
PIPELINE – MULTIPLE VALUE DRIVERS Indication Program Discovery Preclinical Phase I Phase II Target: FcγRIIB NHL (MCL, MZL, iFL) BI-1206 / rituximab Solid cancer αFcγRIIB 2019 Solid cancer BI-1607 2019 Target: Tumor associated regulatory T cells (Tregs) Solid cancer αCTLA-4-GM-CSF-VV 2020 BI-1808/αTN
Slide 11: Development programs – solid cancer focus
1. Introduction to BioInvent 2. Development programs 1 – solid cancer focus 3. Management and board1 4. Key milestones 1 A. Appendix 1 11
Slide 12: FcgRIIB – a single inhibitory antibody checkpoint
FcgRIIB – A SINGLE INHIBITORY ANTIBODY CHECKPOINT TO UNLOCK ANTI-CANCER IMMUNITY Antibody checkpoints Activating receptors Inhibitory receptors COMMENTS COMMENTS Activating FcgRs enhance Inhibitory FcgR suppress antibody-induced immune antibody-induced immune effector cell responses effector cel
Slide 13: FcgRIIB – a single inhibitory antibody checkpoint
FcgRIIB – A SINGLE INHIBITORY ANTIBODY CHECKPOINT TO UNLOCK ANTI-CANCER IMMUNITY Antibody checkpoints T cell checkpoints Innate immunity Adaptive immunity Part of the immune system that kills tumor Activates Part of the immune that eliminates the pathogens cells, but also activates and shapes the an
Slide 14: FcgR interactions co-determine efficacy of checkpoint inhibitor antibodies
FcgR-INTERACTIONS CO-DETERMINE EFFICACY OF CHECKPOINT INHIBITOR ANTIBODIES Fc effector function contributes to the activity of Fcγ receptors modulate the anti-tumor activity of human anti-CTLA-4 antibodies1 antibodies targeting the PD-1/PD-L1 axis2 “FcγR engagement augments the anti-tumor activity o
Slide 15: FcgR interactions determine efficacy of emerging immune modulatory antibodies
FcgR-INTERACTIONS DETERMINE EFFICACY OF EMERGING IMMUNE MODULATORY ANTIBODIES FcγRs determine efficacy and mechanism-of-action of FcγRs determine intatumoral anti-IL-2R antibody- antibodies to co-stimulatory immune checkpoints1 mediated Treg deletion1 1. IL-2R highly expressed on Tregs in blood, lym
Slide 16: BI-1206 in non-Hodgkin lymphoma: turbocharging anti-CD20
BI-1206 IN NON-HODGKIN LYMPHOMA TURBOCHARGING ANTI-CD20 Rituximab is effective when bound The immune cells fails to attack the tumor cell to CD20 on the cell surface, but its efficacy is hampered by FcgRIIB- mediated endocytosis Rituximab is a monoclonal antibody PRE BI-1206 (Rituxan®, Mabthera®
Slide 17: BI-1206: Cutting both ways
BI-1206: CUTTING BOTH WAYS BI-1206 BLOCKS RITUXIMAB INTERNALIZATION AND IMPROVES ITS ANTI-TUMOR ACTIVITY Human CD20 FcγRIIB double transgenic mice Humanized model of relapsed / refractory CLL1 B cell depletion in vivo BOOSTING RITUXIMAB’S EFFECT OVERCOMING RESISTANCE % objective responders (blue) Co
Slide 18: BI-1206: Expanding therapeutic potential - Phase I/IIa study
BI-1206: EXPANDING THERAPEUTIC POTENTIAL - PHASE I/IIA STUDY STUDY OVERVIEW − A multicenter, open label, Phase I/IIa study in relapsed or refractory indolent Non-Hodgkin Lymphoma (iNHL) patients enriched with Mantle Cell Lymphoma – approximately 24 patients across sites in US & EU − High proportion
Slide 19: BI-1206: Value proposition – key segments and value drivers
BI-1206: VALUE PROPOSTION – KEY SEGMENTS & VALUE DRIVERS KEY SUB-SEGMENTS OF NON-HODGKIN LYMPHOMA (NHL) Value drivers Safety, chemo-free regimen and scientific rationale in anti-CD20 refractory B-cell lymphoma are key drivers of BI-1206 attractiveness. First-in-class in hematology - no direct comp
Slide 20: Targeting Tregs and TAMs to mitigate immune suppression
TARGETING TREGS AND TAMS TO MITIGATE IMMUNE SUPPRESSION Regulatory T cells (Tregs) can Developing antibodies that act on Tregs via novel or validated targets substantially inhibit immune responses, enabling tumor cells to 1. 2. 3. TARGETING TREGS escape detection. BioInvent is utilizing its F.I.
Slide 21: mAbs + oncolytic virus to target solid tumors
MABS + ONCOLYTIC VIRUS TO TARGET SOLID TUMORS 50/50 PARTNERSHIP WITH TRANSGENE TO DEVELOP NEXT GENERATION ONCOLYCTIC VIRUS MAbs and oncolytic virus attacking the solid tumor ABOUT THE COLLABORATION BioInvent’s CTLA-4 mAB BioInvent and Transgene collaborate to co-develop oncolytic virus (OV) candid
Slide 22: Management and board
1. Introduction to BioInvent 2. Development programs 1 – solid cancer focus 3. Management and board1 4. Key milestones 1 A. Appendix 1 22
Slide 23: Management Team
MANAGEMENT TEAM Martin Welschof Björn Frendéus Andres McAllister Chief Executive Officer Chief Scientific Officer Chief Medical Officer Holdings: - Holdings: 317,151 shares; 75,333 options Holdings: 12,556 options Ph.D. (Dr.rer.nat.) in recombinant antibody technology. Post-doctoral Doctor of Immuno
Slide 24: Board of Directors
BOARD OF DIRECTORS Leonard Kruimer An van Es Johansson Dharminder Chahal Chairman Board member Board member Holdings: - Holdings: 55,360 shares Holdings: 305,360 shares MBA. Provides presently interim management solutions and consulting M.D. VP and Head of Medical Affairs at Swedish Orphan Biovitrum
Slide 25: Key milestones
1. Introduction to BioInvent 2. Development programs 1 – solid cancer focus 3. Management and board1 4. Key milestones 1 A. Appendix 1 25
Slide 26: Key Milestones
KEY MILESTONES TIMING EVENTS Start Phase I/IIa BI-1206/rituximab combination trial in NHL H2 2018 Preclinical rationale Anti-CTLA-4/oncolytic virus, SITC Poster BI-1206 /rituximab orphan drug designation (ODD) in mantle cell lymphoma Podium Presentation SLAS 2019 Washington on F.I.R.S.T tm H
Slide 27: Appendix
1. Introduction to BioInvent 2. Development programs 1 – solid cancer focus 3. Management and board1 4. Key milestones 1 A. Appendix 1 27
Slide 28: Proprietary manufacturing platform since 1988
PROPRIETARY MANUFACTURING PLATFORM SINCE 1988 Supports fast and flexible production of proprietary programs State of the art single use bioreactor (SUB) technology: 40L -1,000L batch sizes Approved for Phase l to lll production Track record of 30 years inspections Consistent source of near
Slide 29: Shareholder List
SHAREHOLDER LIST Largest shareholders 30 September 2018 No. of shares Percentage of capital and votes (%) Comments Van Herk Investments B.V. 29,091,272 8.3 In March 2018 the Company successfully Omega Fund IV, LP 28,352,982 8.1 completed a directed share issue of USD 10 IMEurope (Institut Mérieux)
Slide 30: Overview of BioInvent's competitive landscape
OVERVIEW OF BIOINVENT’S COMPETITIVE LANDSCAPE Compound BI-1206 Ibrutinib Acalabrutinib Copanlisib1 Venetoclax Company Target FcgRIIB BTK inhibitor “2nd generation BTK inh. PI3k inhibitor BCL2 inhibitor Development phase Phase I Marketed Marketed in MCL Marketed Marketed 2 Indication iNHL and MCL NHL
Slide 31: Value Proposition
VALUE PROPOSITION Safety, chemo-free regimen and scientific rationale in anti-CD20 refractory B-cell lymphoma are key drivers of BI 1206 attractiveness FL MZL MCL Attractive opportunities: Attractive opportunities: Attractive opportunities: Key • 2nd Line (Relapsed/ refractory) • 2nd Line+ (Relapsed
Slide 32: Market & Disease Overview – MCL
MARKET & DISEASE OVERVIEW – MCL 32 Source: Defined Health
Slide 33: Market & Disease Overview – FL
MARKET & DISEASE OVERVIEW – FL 33 Source: Defined Health
Slide 34: Market & Disease Overview – MZL
MARKET & DISEASE OVERVIEW – MZL 34 Source: Defined Health
BioInvent International — Investor Day (December 2018) on 6ix